Prolonged survival of patients with lung adenocarcinoma expressing XAGE-1b and HLA class I antigens

Cancer Immunity

Volumn 8, Issue , 2008, Pages

  Kikuchi, Eiki ^a   Yamazaki, Koichi ^a   Nakayama, Eiichi ^b   Sato, Shuichiro ^b   Uenaka, Akiko ^b   Yamada, Noriyuki ^a   Oizumi, Satoshi ^a   Dosaka Akita, Hirotoshi ^c   Nishimura, Masaharu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

HLA class I antigen; Human; Immunohistochemistry; Non small cell lung cancer; Prognosis; XAGE 1

Indexed keywords

CANCER TESTIS ANTIGEN; HLA ANTIGEN CLASS 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY USO9 13; PROTEIN XAGE 1B; UNCLASSIFIED DRUG; TUMOR ANTIGEN; XAGE1A PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL DENSITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; PROTEIN EXPRESSION; ADENOCARCINOMA; IMMUNOLOGY; KAPLAN MEIER METHOD; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; SURVIVAL RATE;

ADENOCARCINOMA; AGED; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE;

EID: 52049127030     PISSN: None     EISSN: 14249634     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/ testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-625. (PMID: 16034368)
2. Scanlan MJ, Simpson AJ, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun 2004; 4: 1. URL: http://www.cancerimmunity.org/v4p1/031220.htm
3. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10: 281-287. (PMID: 10204484)
4. Coulie PG, Karanikas V, Colau D, Lurquin C, Landry C, Marchand M, Dorval T, Brichard V, Boon T. A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3. Proc Natl Acad Sci U S A 2001; 98: 10290-10295. (PMID: 11517302)
5. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647. (PMID: 1840703)
6. Jäger E, Karbach J, Gnjatic S, Jäger D, Maeurer M, Atmaca A, Arand M, Skipper J, Stockert E, Chen YT, Old LJ, Knuth A. Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51. Cancer Immun 2002; 2: 12. URL: http://www. cancerimmunity.org/v2p12/020812.htm
7. Jäger E, Jäger D, Karbach J, Chen YT, Ritter G, Nagata Y, Gnjatic S, Stockert E, Arand M, Old LJ, Knuth A. Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101- 0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med 2000; 191: 625-630. (PMID: 10684854)
8. Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, Jäger E, Knuth A, Chen YT, Old LJ. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res 2006; 95: 1-30. (PMID: 16860654)
9. Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, Zerkowski HR, Heberer M, Spagnoli GC. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer 2006; 120: 337-343. (PMID: 17066423)
10. Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, Mirlacher M, Gambazzi F, Harder F, Heberer M, Sauter G, Spagnoli GC. Tissue microarray evaluation of Melanoma antigen E (MAGE) tumor associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg 2002; 236: 785-793. (PMID: 12454517)
11. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ, Altorki NK. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005; 11: 8055-8062. (PMID: 16299236)
12. Brinkmann U, Vasmatzis G, Lee B, Pastan I. Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res 1999; 59: 1445-1448. (PMID: 10197611)
13. Zendman AJ, van Kraats AA, den Hollander AI, Weidle UH, Ruiter DJ, van Muijen GN. Characterization of XAGE-1b, a short major transcript of cancer/testis-associated gene XAGE-1, induced in melanoma metastasis. Int J Cancer 2002; 97: 195-204. (PMID: 11774264)
14. Egland KA, Kumar V, Duray P, Pastan I. Characterization of overlapping XAGE-1 transcripts encoding a cancer testis antigen expressed in lung, breast, and other types of cancers. Mol Cancer Ther 2002; 7: 441-450. (PMID: 12479262)
15. Nakagawa K, Noguchi Y, Uenaka A, Sato S, Okumura H, Tanaka M, Shimono M, Ali Eldib AM, Ono T, Ohara N, Yoshino T, Yamashita K, Tsunoda T, Aoe M, Shimizu N, Nakayama E. XAGE-1 expression in non-small cell lung cancer and antibody response in patients. Clin Cancer Res 2005; 11: 5496-5503. (PMID: 16061866)
16. Sato S, Noguchi Y, Ohara N, Uenaka A, Shimono M, Nakagawa K, Koizumi F, Ishida T, Yoshino T, Shiratori Y, Nakayama E. Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors. Cancer Immun 2007; 7: 5. URL: http:// www.cancerimmunity.org/v7p5/070103.htm
17. Ali Eldib AM, Ono T, Shimono M, Kaneko M, Nakagawa K, Tanaka R, Noguchi Y, Nakayama E. Immunoscreening of cDNA library from a lung cancer cell line using autologous patient serum: identification of XAGE-1b as a dominant antigen and its immunogenicity in lung adenocarcinoma. Int J Cancer 2004; 108: 558-559. (PMID: 14696120)
18. Kikuchi E, Yamazaki K, Torigoe T, Cho Y, Miyamoto M, Oizumi S, Hommura F, Dosaka-Akita H, Nishimura M. HLA class I antigen expression is associated with favorable prognosis in early stage nonsmall cell lung cancer. Cancer Sci 2007; 98: 1424-1430. (PMID: 17645781)
19. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002; 3: 999-1005. (PMID: 12407407)
20. Shimono M, Uenaka A, Noguchi Y, Sato S, Okumura H, Nakagawa K, Kiura K, Tanimoto M, Nakayama E. Identification of DR9-restricted XAGE antigen on lung adenocarcinoma recognized by autologous CD4 T-cells. Int J Oncol 2007; 30: 835-840. (PMID: 17332921)
21. Yazawa T, Kamma H, Fujiwara M, Matsui M, Horiguchi H, Satoh H, Fujimoto M, Yokoyama K, Ogata T. Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J Pathol 1999; 187: 191-199. (PMID: 10365094)
22. The World Health Organization histological typing of lung tumours. Second edition. Am J Clin Pathol 1982; 77: 123-136. (PMID: 7064914)
23. American Joint Committee on Cancer. Lung. In: Manual for staging of cancer. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. (Eds.) Philadelphia (PA): Lippincott Williams & Wilkins; 1992; 115-122.